The Phase 3 start is a positive catalyst for ALT, but the 2029 readout limits near-term upside. Monitor enrollment updates, potential interim analysis disclosures, and data from the ongoing AUD (RECLAIM) and ALD (RESTORE) trials for additional catalysts in the next 12-18 months.
Price Chart
Executive Summary
Altimmune initiated the PERFORMA Phase 3 registrational trial of pemvidutide in MASH, a key milestone following positive Phase 2b data and FDA Breakthrough Therapy Designation. The trial has two cohorts (990 patients for accelerated approval biopsy endpoint at 52 weeks, 800 for safety) with data readout expected in 2029. This de-risks the lead pipeline asset and opens a potential multi-billion dollar MASH market, though the long timeline tempers near-term impact.
Key Facts
- Phase 3 PERFORMA trial for pemvidutide in MASH initiated (enrollment began)
- Trial includes two cohorts: ~990 patients for accelerated approval (52-week biopsy endpoint) and ~800 for safety
- 52-week data readout anticipated in 2029; event-driven design with interim analysis
- FDA granted Fast Track and Breakthrough Therapy Designation for pemvidutide in MASH
- Positive Phase 2b IMPACT data showed statistically significant MASH resolution and fibrosis improvement
- Pemvidutide is a balanced 1:1 glucagon/GLP-1 dual receptor agonist with additional programs in AUD and ALD
- CEO cited trial initiation within 3 months of securing funding, highlighting execution speed
Financial Impact
No specific financial figures disclosed; trial initiation is a pivotal catalyst for a $552M market cap biotech with lead asset in a large MASH market (millions of patients globally)
Risk Factors
- Clinical trial risk: Phase 3 may fail to meet endpoints despite positive Phase 2b
- Long timeline: 52-week readout not until 2029, with full approval based on clinical outcomes at ~60 months
- Capital needs: substantial additional financing likely required to complete the trial and scale manufacturing
- Competition: MASH space is crowded with approved therapies (Rezdiffra) and many late-stage candidates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3337439 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | 8-K | $2.97 $2.67 | ▼ −10.10% | ▼ −12.05% | $2.09 (−29.63%) |
Aug 12, 2026 10w ago | 8-K | $2.93 $3.12 | ▲ +6.48% | ▲ +6.93% | $2.09 (−28.67%) |
Aug 12, 2026 10w ago | Press Release | $2.93 $3.12 | ▲ +6.48% | ▲ +6.93% | $2.09 (−28.67%) |
Aug 6, 2026 11w ago | Institutional Cluster | $3.01 $2.88 | ▼ −4.32% | ▼ −5.53% | $2.09 (−30.56%) |
Aug 5, 2026 11w ago | Press Release | $3.03 $2.93 | ▼ −3.30% | ▼ −3.65% | $2.09 (−31.02%) |
Aug 3, 2026 12w ago | Press Release | $3.00 $3.05 | ▲ +1.67% | ▼ −0.36% | $2.09 (−30.33%) |
Jul 28, 2026 12w ago | 8-K | $2.99 $3.00 | ▲ +0.33% | ▼ −1.93% | $2.09 (−30.10%) |
May 28, 2026 21w ago | Press Release | $3.07 $2.87 | ▼ −6.51% | ▼ −6.47% | $2.09 (−31.92%) |
May 27, 2026 21w ago | Press Release | $2.98 $2.90 | ▼ −2.68% | ▼ −3.89% | $2.09 (−29.87%) |
May 13, 2026 23w ago | 8-K | $3.02 $2.74 | ▼ −9.27% | ▼ −8.11% | $2.09 (−30.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers